Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice

Abstract

Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods: A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara®) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan–Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.

Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long‐term experience

“…The mean age of our cohort (56.2 years) was similar to that in other apremilast studies, 10,12,14,16 but older than in our ustekinumab, 20 adalimumab, 21 and secukinumab series, 22 …”

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

“…49 Studies specifically addressing the influence of DM on risankizumab treatment response are lacking, but drug survival in relation to the presence of diabetes seemed to be inconsistent in ustekinumab and guselkumab. 11,12 In contrast to the consistently higher curves in Group S than Group O, only PASI 75 curve in Group DM-significantly surpassed that of Group DM+. For the other effectiveness endpoints, BSA 50/75/90 curves in Group DM+ were even numerically higher than Group DM-counterparts without statistical significance.…”

“…Nonetheless, when adjusted for other confounders such as obesity, the odds ratio of achieving PASI 75/90 for DM patients on IL‐23 inhibitors did not reach statistical significance 49 . Studies specifically addressing the influence of DM on risankizumab treatment response are lacking, but drug survival in relation to the presence of diabetes seemed to be inconsistent in ustekinumab and guselkumab 11,12 . In contrast to the consistently higher curves in Group S than Group O, only PASI 75 curve in Group DM– significantly surpassed that of Group DM+.…”

“…Multiple factors can contribute to the difference in the treatment response of biologics, including the presence of comorbidities, 6 the number of prior biologics used, 7,8 disease duration 9,10 and body weight. The presence of comorbidities, especially diabetes mellitus (DM), has been shown to affect drug survival of biologics in some studies, 11 but the result seemed to be inconsistent 12 . Body weight is also positively associated with the severity of psoriasis, but its effect on the efficacy of biologics is controversial 10 .…”

“…The presence of comorbidities, especially diabetes mellitus (DM), has been shown to affect drug survival of biologics in some studies, 11 but the result seemed to be inconsistent. 12 Body weight is also positively associated with the severity of psoriasis, but its effect on the efficacy of biologics is controversial. 10 In previous studies, Caucasian patients weigh on average 90-100 kgs and Asian patients weigh 75-80 kgs.…”